左乙拉西坦与苯巴比妥治疗新生儿惊厥的随机对照试验
这项多中心、随机、盲法、对照IIb期试验比较左乙拉西坦与苯巴比妥作为新生儿惊厥一线治疗的有效性和安全性。相对危险度0.35[95%CI:0.22-0.56]);苯巴比妥不良反应更多但无统计学意义。
要点
- 苯巴比妥作为新生儿惊厥一线治疗,24小时无发作率显著高于左乙拉西坦。
- 左乙拉西坦剂量从40mg/kg增至60mg/kg,疗效提高7.5%。
- 苯巴比妥组不良反应更多,但差异无统计学意义。
核心结论
- 在本IIb期研究中,苯巴比妥治疗新生儿惊厥的疗效优于左乙拉西坦。
- 苯巴比妥治疗的不良反应发生率更高。
- 需要开展左乙拉西坦更高剂量的研究以及具有长期结局指标的确定性研究。
研究设计与样本
- 多中心、随机、盲法、对照IIb期试验,研究左乙拉西坦与苯巴比妥作为任何病因新生儿惊厥一线治疗的有效性和安全性。
- 主要结局为24小时完全无惊厥发作,由2名神经电生理医生独立审阅脑电图评估。
- 改良意向性治疗人群:苯巴比妥组30例,左乙拉西坦组53例。
主要发现
- 左乙拉西坦剂量从40mg/kg增至60mg/kg,疗效提高7.5%。
- 苯巴比妥组观察到更多不良反应,但差异无统计学意义。
关键数值与推荐
- 主要结局:24小时完全无惊厥发作,基于2名神经电生理医生独立脑电图审阅。
- 左乙拉西坦剂量从40mg/kg增至60mg/kg,疗效提高7.5%。
临床怎么用
- 对于新生儿惊厥,苯巴比妥作为一线治疗的24小时无发作率高于左乙拉西坦。
- 左乙拉西坦剂量增至60mg/kg可提高疗效,但需进一步研究更高剂量。
- 苯巴比妥不良反应更多,临床决策需权衡疗效与安全性。
局限性
- 本研究为IIb期试验,样本量有限(苯巴比妥组30例,左乙拉西坦组53例)。
- 缺乏长期结局指标,需要确定性研究评估远期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There are no US Food and Drug Administration-approved therapies for neonatal seizures. Phenobarbital and phenytoin frequently fail to control seizures. There are concerns about the safety of seizure medications in the developing brain. Levetiracetam has proven efficacy and an excellent safety profile in older patients; therefore, there is great interest in its use in neonates. However, randomized studies have not been performed. Our objectives were to study the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment of neonatal seizures. METHODS: The study was a multicenter, randomized, blinded, controlled, phase IIb trial investigating the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment for neonatal seizures of any cause. The primary outcome measure was complete seizure freedom for 24 hours, assessed by independent review of the EEGs by 2 neurophysiologists. RESULTS: Eighty percent of patients (24 of 30) randomly assigned to phenobarbital remained seizure free for 24 hours, compared with 28% of patients (15 of 53) randomly assigned to levetiracetam (P < .001; relative risk 0.35 [95% confidence interval: 0.22-0.56]; modified intention-to-treat population). A 7.5% improvement in efficacy was achieved with a dose escalation of levetiracetam from 40 to 60 mg/kg. More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). CONCLUSIONS: In this phase IIb study, phenobarbital was more effective than levetiracetam for the treatment of neonatal seizures. Higher rates of adverse effects were seen with phenobarbital treatment. Higher-dose studies of levetiracetam are warranted, and definitive studies with long-term outcome measures are needed.
引用
- Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics. 2020. PMID: 32385134. doi:10.1542/peds.2019-3182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。